Wang T, Osborne N, Rechtenwald J, et al. - A retrospective review was conducted of a prospectively gathered database of individuals with in-transit malignant melanoma who underwent cytoreduction and HILP/HILI between 2013 and 2017 in order to hypothesize that combining cytoreduction with no-tourniquet HILP/HILI was safe in individuals of all ages and lead to enduring responses. Considerably higher disease burdens was seen in HILP patients vs HILI patients. Comprehensive response rates for HILP and HILI were 95% and 75% and 47% and 50%, respectively at 3 months and at 1 year along with 100% 1-year survival rates for each HILP and HILI individuals. Three-year survival rates were 57% (HILP), 52% (HILI) and 68% (patients >80 years old). Hence, for in-transit metastatic melanoma of the extremity, combining cytoreduction with no-tourniquet HILP/HILI led to 100% survival irrespective of age at 1 year and 68% 3-year survival in individuals over 80 without any progress in adverse events.